Evidence map›Paper›PMID 29152051›Full record

ArticleACS medicinal chemistry letters2017

χ-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds.

Olivier Van der Poorten, Robin Van Den Hauwe, Emilie Eiselt, Cecilia Betti, Karel Guillemyn, Nga N Chung, François Hallé, Frédéric Bihel, Peter W Schiller, Dirk Tourwé and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Design, Synthesis, andACS pharmacology & translational science · 2024
    Article
  4. Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13.ACS pharmacology & translational science · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Olivier Van der PoortenResearch Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Robin Van Den HauweResearch Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Emilie EiseltDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Centre de Recherche du CHU de Sherbrooke, Centre d'Excellence en Neurosciences de l'Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbrooke, Québec J1H 5N4,Canada.
Cecilia BettiResearch Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Karel GuillemynResearch Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Nga N ChungDepartment of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, 110 Avenue Des Pins Ouest, Montreal, QC H2W1R7, Canada.
François HalléUMR7200, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 Route du Rhin, 67401 Illkirch, France.
Frédéric BihelUMR7200, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 Route du Rhin, 67401 Illkirch, France.
Peter W SchillerDepartment of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, 110 Avenue Des Pins Ouest, Montreal, QC H2W1R7, Canada.
Dirk TourwéResearch Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Philippe SarretDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Centre de Recherche du CHU de Sherbrooke, Centre d'Excellence en Neurosciences de l'Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbrooke, Québec J1H 5N4,Canada.
Louis GendronDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Centre de Recherche du CHU de Sherbrooke, Centre d'Excellence en Neurosciences de l'Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbrooke, Québec J1H 5N4,Canada.
Steven BalletResearch Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.

Funding

DEVELOPMENT OF RECEPTOR-SPECIFIC OPIOID PEPTIDE ANALOGSR01DA004443 · NIDA · CLINICAL RESEARCH INSTITUTE OF MONTREAL · PI SCHILLER, PETER W · 1987 to 2016
$2.0M
DEVELOPMENT OF RECEPTOR SPECIFIC OPIOID PEPTIDE ANALOGSR37DA004443 · NIDA · CLINICAL RESEARCH INSTITUTE OF MONTREAL · PI SCHILLER, PETER W · 1997 to 2003
$621k
NIDA NIH HHS R01 DA004443NIDA NIH HHS R37 DA004443
6 · The paper itself

Abstract

Herein, the synthesis of novel conformationally constrained amino acids, 4-amino-8-bromo-2-benzazepin-3-one (8-Br-Aba), 3-amino-3,4-dihydroquinolin-2-one, and regioisomeric 4-amino-naphthoazepinones (1- and 2-Ana), is described. Introduction of these constricted scaffolds into the

Identifiers

PMID29152051
PMCPMC5683700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.